Alembic Pharmaceuticals Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Alembic Pharmaceuticals şirketinin toplam hissedar öz sermayesi ₹48.2B ve toplam borcu ₹5.1B olup, bu da borç-öz sermaye oranını 10.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹64.5B ve ₹16.3B dir. Alembic Pharmaceuticals 'in FAVÖK'ü ₹7.0B faiz karşılama oranı 13.2 dur. Şirketin ₹1.2B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.
Anahtar bilgiler
10.7%
Borç/özkaynak oranı
₹5.13b
Borç
| Faiz karşılama oranı | 13.2x |
| Nakit | ₹1.20b |
| Eşitlik | ₹48.18b |
| Toplam yükümlülükler | ₹16.27b |
| Toplam varlıklar | ₹64.46b |
Son finansal sağlık güncellemeleri
Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?
Sep 03
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly
Jun 03Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22Recent updates
Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price
Sep 25Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?
Sep 03Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 13Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher
Jul 20Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly
Jun 03Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?
May 11Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 08Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%
Jan 21Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Apr 13Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jan 04We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now
Nov 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden
Aug 10Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Jul 20We Think Alembic Pharmaceuticals (NSE:APLLTD) Is Taking Some Risk With Its Debt
May 05Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: APLLTD 'nin kısa vadeli varlıkları ( ₹30.8B ) kısa vadeli yükümlülüklerini ( ₹14.6B ) aşıyor.
Uzun Vadeli Yükümlülükler: APLLTD şirketinin kısa vadeli varlıkları ( ₹30.8B ) uzun vadeli yükümlülüklerini ( ₹1.7B ) aşmaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: APLLTD 'nin net borç/öz sermaye oranı ( 8.2% ) tatmin edici olarak değerlendirilmektedir.
Borcun Azaltılması: APLLTD 'nin borç/öz sermaye oranı son 5 yılda 41.5% seviyesinden 10.7% seviyesine düştü.
Borç Kapsamı: APLLTD 'nin borcu işletme nakit akışı ( 156.5% ) tarafından iyi bir şekilde karşılanmaktadır.
Faiz Kapsamı: APLLTD 'in borcuna ilişkin faiz ödemeleri EBIT ( 13.2 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.